NCT07209462 - Study of MRM-3379 in Male Participants With Fragile X Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Fragile X Syndrome

Interventions

DRUG

Low dose of MRM-3379

Oral capsule

DRUG

Middle Dose of MRM-3379

Oral capsule

DRUG

High dose of MRM-3379

Oral capsule

DRUG

Placebo

Capsules matched to study drug without the active pharmaceutical ingredient

DRUG

Low dose of MRM-3379 Open-Label

Oral capsule

Trial Locations (5)

NOT_YET_RECRUITING

Suburban Research Associates, Media

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

RECRUITING

California Clinical Trials Medical Group(CCTMG) managed by Parexel, Glendale

NOT_YET_RECRUITING

Amnova Clinical Research, LLC, Irvine

NOT_YET_RECRUITING

Boston Children's Hospital, Boston